1795 — Lotus Pharmaceutical Share News
0.000.00%
Last trade - 00:00- TWD48.13bn
- TWD100.25bn
- TWD20.51bn
Brief: enz Therapeutics Submits NDA for LNZ100 (Vizz) in South Korea to Treat Presbyopia
Brief: Lotus Pharmaceutical Says Unit Has Closed Deal In Vietnam
Brief: Fuji Pharma: Marketing Approval For Generic Lenalidomide, The First Collaboration Product With Taiwan's Lotus
Brief: Amarin And Lotus Pharmaceuticals Announce Exclusive Partnership In Southeast Asia And South Korea
Brief: Pharma Mar Announces Its Partner Lotus Pharmaceutical Receives Approval For Zepzelca In Taiwan
Brief: NRx Pharmaceuticals, Lotus Pharmaceuticals And Alvogen To Collaborate To Develop And Commercialize NRX-101
Brief: Lotus Pharmaceutical Says Its Nintedanib Capsules Has Obtained Tentative Aproval From U.S. FDA
Brief: Lotus Pharmaceutical Says Lenalidomide, Its Blood Cancer Drug, Has Been Officially Launched In The U.S.
Brief: Glenmark Pharma's Swiss Unit Enters Licensing Deal With Lotus International
Thai oil firm PTT expands pharma business with $475 mln Alvogen deal
Brief: PTT Says On 18 Nov, Approved Unit To Acquire All Stakes In Alvogen Emerging Markets Holdings
Brief: Pharma Mar Signs License Agreement With Lotus Pharmaceutical To Commercialize Lurbinectedin In Taiwan
Brief: Fuji Pharma Co Says To Form Capital Tie-Up With Taiwan's Lotus Pharmaceutical